CANY
NBIX icon

Caxton Associates (New York)’s Neurocrine Biosciences NBIX Stock Holding History

Caxton Associates (New York)’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-18,121
Closed -$2.49M – 608
2024
Q2 		$2.49M Sell
18,121
-407
-2% -$55.8K 0.09% 126
2024
Q1 		$2.56M Buy
+18,528
New +$2.53M 0.14% 100
2023
Q1 		– Sell
-4,869
Closed -$582K – 590
2022
Q4 		$582K Buy
4,869
+1,874
+63% +$219K 0.04% 211
2022
Q3 		$318K Buy
+2,995
New +$304K 0.04% 316
2020
Q3 		– Sell
-9,510
Closed -$1.16M – 448
2020
Q2 		$1.16M Buy
+9,510
New +$1.05M 0.1% 65
2020
Q1 		– Sell
-4,061
Closed -$437K – 524
2019
Q4 		$437K Buy
+4,061
New +$425K 0.06% 197

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Caxton Associates (New York)'s NBIX Position: Q3 2024 in Review

Caxton Associates (New York) sold out of Neurocrine Biosciences (NBIX) in Q3 2024, closing a stake of 18,121 shares — an estimated $2.49M sold.

Caxton Associates (New York) first reported a position in NBIX in Q4 2019 and held it in 6 quarters. The position peaked at $2.56M in Q1 2024. 574 funds tracked by Wall St. Rank hold NBIX as of Q3 2024.

  • Caxton Associates (New York) reported no remaining Neurocrine Biosciences position as of Q3 2024 after selling out during the quarter.
  • Caxton Associates (New York) sold 18,121 Neurocrine Biosciences shares in Q3 2024, an estimated $2.49M.
  • Caxton Associates (New York) first reported a position in Neurocrine Biosciences in Q4 2019 and held it in 6 quarters.
  • Caxton Associates (New York)'s Neurocrine Biosciences position peaked at $2.56M in Q1 2024.
  • 574 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2024.

Based on Caxton Associates (New York)'s 13F filing for Q3 2024, filed 14 Nov 2024.